CL2015002491A1 - Uso de (rs)-s-ciclopropil-s-(4-{[4-{[(1r,2r)-2-hidroxi-1-metilpropil]oxi}-5-(trifluorometil)pirimidin-2-il]amino}fenil)sulfoximida para tratar tumores específicos - Google Patents

Uso de (rs)-s-ciclopropil-s-(4-{[4-{[(1r,2r)-2-hidroxi-1-metilpropil]oxi}-5-(trifluorometil)pirimidin-2-il]amino}fenil)sulfoximida para tratar tumores específicos

Info

Publication number
CL2015002491A1
CL2015002491A1 CL2015002491A CL2015002491A CL2015002491A1 CL 2015002491 A1 CL2015002491 A1 CL 2015002491A1 CL 2015002491 A CL2015002491 A CL 2015002491A CL 2015002491 A CL2015002491 A CL 2015002491A CL 2015002491 A1 CL2015002491 A1 CL 2015002491A1
Authority
CL
Chile
Prior art keywords
sulfoximide
methylpropyl
pyrimidin
cyclopropyl
oxy
Prior art date
Application number
CL2015002491A
Other languages
English (en)
Inventor
Gerhard Siemeister Dr
Ribrag Vincent
Camara-Clayette Valérie
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50189709&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002491(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CL2015002491A1 publication Critical patent/CL2015002491A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)

Abstract

Uso de (R)-S-ciclopropil-S-(4-{[4-{[(1R,2R)-2-hidroxi-1-metilpropil]oxi}-5-(trifluorometil)pirimidin-2-il]amino}fenil)sulfoximida y/o (S)-S-ciclopropil-S-(4-{[4-{[(1R,2R)-2-hidroxi-1-metilpropil]oxi}-5-(trifluorometil)pirimidin-2-il]amino}fenil)sulfoximida para tratar tumores específicos.
CL2015002491A 2013-03-07 2015-09-07 Uso de (rs)-s-ciclopropil-s-(4-{[4-{[(1r,2r)-2-hidroxi-1-metilpropil]oxi}-5-(trifluorometil)pirimidin-2-il]amino}fenil)sulfoximida para tratar tumores específicos CL2015002491A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102013203913 2013-03-07

Publications (1)

Publication Number Publication Date
CL2015002491A1 true CL2015002491A1 (es) 2016-01-15

Family

ID=50189709

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002491A CL2015002491A1 (es) 2013-03-07 2015-09-07 Uso de (rs)-s-ciclopropil-s-(4-{[4-{[(1r,2r)-2-hidroxi-1-metilpropil]oxi}-5-(trifluorometil)pirimidin-2-il]amino}fenil)sulfoximida para tratar tumores específicos

Country Status (19)

Country Link
US (1) US20160045496A1 (es)
EP (1) EP2964259A1 (es)
JP (1) JP2016513619A (es)
KR (1) KR20150128783A (es)
CN (1) CN105007945A (es)
AP (1) AP2015008753A0 (es)
AU (1) AU2014224737A1 (es)
BR (1) BR112015021550A2 (es)
CA (1) CA2904149A1 (es)
CL (1) CL2015002491A1 (es)
EA (1) EA201591625A1 (es)
HK (1) HK1211229A1 (es)
IL (1) IL240977A0 (es)
MX (1) MX2015011800A (es)
PH (1) PH12015501969A1 (es)
SG (1) SG11201506755XA (es)
TN (1) TN2015000387A1 (es)
TW (1) TW201501712A (es)
WO (1) WO2014135460A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010014426A1 (de) * 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
US9241941B2 (en) * 2012-09-20 2016-01-26 Memorial Sloan-Kettering Cancer Center Methods for treatment of lymphomas with mutations in cell cycle genes

Also Published As

Publication number Publication date
IL240977A0 (en) 2015-11-30
HK1211229A1 (en) 2016-05-20
SG11201506755XA (en) 2015-09-29
AU2014224737A1 (en) 2015-09-24
EA201591625A1 (ru) 2016-03-31
KR20150128783A (ko) 2015-11-18
CA2904149A1 (en) 2014-09-12
JP2016513619A (ja) 2016-05-16
US20160045496A1 (en) 2016-02-18
BR112015021550A2 (pt) 2017-07-18
TN2015000387A1 (en) 2017-01-03
AP2015008753A0 (en) 2015-09-30
PH12015501969A1 (en) 2016-01-18
EP2964259A1 (de) 2016-01-13
WO2014135460A1 (de) 2014-09-12
MX2015011800A (es) 2016-01-08
TW201501712A (zh) 2015-01-16
CN105007945A (zh) 2015-10-28

Similar Documents

Publication Publication Date Title
DOP2015000304A (es) Inhibidores cristalinos de bromodominios
EA201792613A1 (ru) Модуляторы cot и способы их применения
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
EA201791007A2 (ru) Соединения и их применения для модуляции гемоглобина
EA201591426A1 (ru) Соединения и их применения для модуляции гемоглобина
EA201790413A1 (ru) Антитела против tigit
EA201691991A1 (ru) Мультиспецифические антитела
EA201591432A1 (ru) Соединения и их применения для модуляции гемоглобина
CR20140576A (es) Sintesis de compuestos heterociclicos
UY34885A (es) Proteínas de unión anti-mesotelina
EA201590997A1 (ru) Соединения и способы их применения
EA201400178A1 (ru) Лечение рака молочной железы
UY34676A (es) ?cuchillo para tratamiento de madera, métodos para galvanizado y tratamiento de superficies de cuchillo para tratamiento de madera?.
EA201391577A1 (ru) Композиция, включающая афлиберцепт, фолиновую кислоту, 5-фторурацил (5-fu) и ириноцетан (folfiri)
EA201492040A1 (ru) Бициклически замещённые урацилы и их применение
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
EA201792096A3 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
ES2721935T3 (es) Anticuerpos anti-BAG3 para uso terapéutico
EA201591709A1 (ru) 5-бром-индирубины
TWD180565S (zh) 塗抹器
UY34840A (es) Vacuna de virus de schmallenberg (sbv), métodos de producción y sus usos
EA201491732A1 (ru) Применение (rs)-s-циклопропил-s-(4-{[4-{[(1r,2r)-2-гидрокси-1-метилпропил]окси}-5-(трифторметил)пиримидин-2-ил]амино}фенил)сульфоксимида для лечения специфических опухолей
CL2015002491A1 (es) Uso de (rs)-s-ciclopropil-s-(4-{[4-{[(1r,2r)-2-hidroxi-1-metilpropil]oxi}-5-(trifluorometil)pirimidin-2-il]amino}fenil)sulfoximida para tratar tumores específicos
DOP2014000206A (es) Nuevas combinaciones para tratar la leucemia mieloide aguda o la leucemia mieloide crónica